HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uysal, E. Articles by Basak, M. Search for Related Content PubMed PubMed Citation Articles by Uysal, E. Articles by Basak, M. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Sensitivity of Immediate and Delayed Gadolinium-Enhanced MRI After Injection of 0.5 M and 1.0 M Gadolinium Chelates for Detecting Multiple Sclerosis Lesions

¹ Department of Radiology, Sisli Etfal Hospital, Etfal Sok, Istanbul 80220, Turkey.
² Department of Neurology, Sisli Etfal Hospital, Istanbul 80220, Turkey.

OBJECTIVE. The purpose of our study was to compare the efficacy of cranial MR images obtained immediately after, 5 minutes after, and 10 minutes after the injection of 0.5-mol/L (Magnevist) and 1.0-mol/L (Gadovist) gadolinium chelates in the detection of active multiple sclerosis (MS) lesions.

MATERIALS AND METHODS. Thirty patients with MS were examined with MRI first with 0.5-mol/L and then, after 24-48 hours, with 1.0-mol/L gadolinium chelates. T1-weighted spin-echo images with magnetization transfer were obtained immediately, 5 minutes, and 10 minutes after the injection of the contrast material. Three radiologists evaluated the gadolinium-enhanced T1-weighted images on a remote MR console (Advantage Windows) in six separate sessions and counted the number of enhancing lesions in consensus.

RESULTS. Significantly fewer enhancing lesions were seen on MR images immediately after the injection of 0.5- and 1.0-mol/L gadolinium chelates (n = 18 and n = 36, respectively; p < 0.05) than at 5 minutes (n = 32 and n = 54; p < 0.05) and 10 minutes (n = 34 and n =55; p < 0.05) after the injection (p < 0.05). Likewise, significantly fewer patients with at least one enhancing lesion after the injection of 0.5- and 1.0-mol/L gadolinium chelates (n = 10 and n = 16; p < 0.05) were found immediately after injection than were found 5 minutes (n = 18 and n = 24; p < 0.05) and 10 minutes (n = 18 and n = 24; p < 0.05) after injection (p < 0.01).

CONCLUSION. The use of 1.0-mol/L gadolinium chelate enables us to detect an increased number of enhancing lesions and patients with active disease. A delay of 5 minutes after the injection of the gadolinium chelate might be sufficient to detect active lesions in patients with MS.

Keywords: contrast media • multiple sclerosis • neuroradiology

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. O'Connor, G. Comi, X. Montalban, J. Antel, E. W. Radue, A. de Vera, H. Pohlmann, L. Kappos, and For the FTY720 D2201 Study Group Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study Neurology, January 6, 2009; 72(1): 73 - 79. [Abstract] [Full Text] [PDF]